Blueprint Medicines Corp

Company Profile

Blueprint Medicines Corp had its IPO on 2015-04-30 under the ticker symbol BPMC.

The company operates in the Healthcare sector and Biotechnology industry. Blueprint Medicines Corp has a staff strength of 651 employees.

Stock update

Shares of Blueprint Medicines Corp opened at $53.39 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $52.75 - $54.33, and closed at $52.81.

This is a -1.38% slip from the previous day's closing price.

A total volume of 341,958 shares were traded at the close of the day’s session.

In the last one week, shares of Blueprint Medicines Corp have increased by +4.29%.

Blueprint Medicines Corp's Key Ratios

Blueprint Medicines Corp has a market cap of $3.31 billion, indicating a price to book ratio of 4.3665 and a price to sales ratio of 9.6137.

In the last 12-months Blueprint Medicines Corp’s revenue was $204.59 million with a gross profit of $177.28 million and an EBITDA of $-542129984. The EBITDA ratio measures Blueprint Medicines Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Blueprint Medicines Corp’s operating margin was -271.72% while its return on assets stood at -29.4% with a return of equity of -89.68%.

In Q1, Blueprint Medicines Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0.9%.

Blueprint Medicines Corp’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-10 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Blueprint Medicines Corp’s profitability.

Blueprint Medicines Corp stock is trading at a EV to sales ratio of 6.9888 and a EV to EBITDA ratio of -2.7283. Its price to sales ratio in the trailing 12-months stood at 9.6137.

Blueprint Medicines Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$1.22 billion

Total Liabilities

$172.68 million

Operating Cash Flow

$172.79 million

Capital Expenditure

$2.58 million

Dividend Payout Ratio

0%

Blueprint Medicines Corp ended 2024 with $1.22 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.22 billion while shareholder equity stood at $414.30 million.

Blueprint Medicines Corp ended 2024 with $0 in deferred long-term liabilities, $172.68 million in other current liabilities, 60000.00 in common stock, $-1962518000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $169.72 million and cash and short-term investments were $961.31 million. The company’s total short-term debt was $28,269,000 while long-term debt stood at $535.35 million.

Blueprint Medicines Corp’s total current assets stands at $900.34 million while long-term investments were $139.15 million and short-term investments were $652.44 million. Its net receivables were $31.30 million compared to accounts payable of $10.56 million and inventory worth $17.52 million.

In 2024, Blueprint Medicines Corp's operating cash flow was $172.79 million while its capital expenditure stood at $2.58 million.

Comparatively, Blueprint Medicines Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$52.81

52-Week High

$79.4

52-Week Low

$37.82

Analyst Target Price

$73.06

Blueprint Medicines Corp stock is currently trading at $52.81 per share. It touched a 52-week high of $79.4 and a 52-week low of $79.4. Analysts tracking the stock have a 12-month average target price of $73.06.

Its 50-day moving average was $54.18 and 200-day moving average was $50.29 The short ratio stood at 6.59 indicating a short percent outstanding of 0%.

Around 74.2% of the company’s stock are held by insiders while 10734.6% are held by institutions.